Ring Nitrogen In The Pentacyclo Ring System Is Shared By Five-membered Cyclo And Six-membered Cyclo (e.g., Vincamine, Etc.) Patents (Class 514/283)
-
Publication number: 20120045434Abstract: The present invention relates to a combination therapy of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer.Type: ApplicationFiled: August 10, 2011Publication date: February 23, 2012Inventors: Kapil Dhingra, Brian Higgins, Kenneth Kolinsky, Richard J. Lee, Brian Lestini, Kathryn Packman, Fei Su
-
Publication number: 20120046310Abstract: The present invention provides compositions for delivering highly water-soluble drugs (such as vinca alkaloids) and methods of using such compositions.Type: ApplicationFiled: August 17, 2011Publication date: February 23, 2012Applicant: Adventrx Pharmaceuticals, Inc.Inventor: Andrew Xian Chen
-
Publication number: 20120045489Abstract: A nano-emulsion injection of Vinca alkaloids and its preparation method are disclosed. The injection is an oil-in-water emulsion injection comprising Vinca alkaloids or their salts, injectable oil, surfactant(s) and injectable water, wherein the average diameter of the droplets of the emulsion is less than 100 nm and the pH of the emulsion is 7-9. The preparation method comprises the steps of preparing the oil phase and the aqueous phase respectively, homogeneously mixing the oil phase and the aqueous phase with high speed, adding the active ingredient, adjusting the pH to 7-9, adding water to constant volume, and homogenizing the emulsion till the average diameter of the droplets being less than 100 nm.Type: ApplicationFiled: December 8, 2009Publication date: February 23, 2012Applicants: SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD., JIANGSU HENGRUI MEDICINE CO., LTD.Inventors: Xinyong Tong, Haifeng Wang, Shuangjin Cui, Li Yu
-
Publication number: 20120045412Abstract: The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.Type: ApplicationFiled: October 28, 2011Publication date: February 23, 2012Applicant: Gilead Sciences, Inc.Inventors: Lawrence S. Melvin, JR., Michael Graupe, Chandrasekar Venkataramani, Juan A. Guerrero
-
Publication number: 20120045524Abstract: The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARP inhibitors in combination with radiotherapy or in combination with other chemotherapeutic agents.Type: ApplicationFiled: November 3, 2011Publication date: February 23, 2012Applicant: ABBOTT LABORATORIESInventors: Wolfgang Wernet, Thomas D. Penning, Vincent L. Giranda
-
Patent number: 8119116Abstract: The present invention relates to methods of treating a cancerous tumor using selective inhibitors of ATP production. The present invention also relates to pharmaceutical preparations comprising such inhibitors and methods for administering them intraarterially directly to a tumor, as well as methods for identifying compositions that selectively inhibitor ATP production for use in the invention.Type: GrantFiled: January 16, 2009Date of Patent: February 21, 2012Assignee: John Hopkins University School of MedicineInventors: Young Hee Ko, Jean-Francois Geschwind, Peter L. Pedersen
-
Publication number: 20120035126Abstract: This invention provides compounds capable of reducing drug resistance in a subject undergoing cancer treatment, methods using the compounds, compositions, and methods for identifying such compounds.Type: ApplicationFiled: January 15, 2010Publication date: February 9, 2012Inventors: Zhenfeng Duan, Francis J. Hornicek
-
Publication number: 20120034216Abstract: The present invention relates to spiroketal compounds that are useful in methods of treating or preventing protozoal infections, parasitic infections, bacterial infections, cell proliferative disorders and anti inflammatory disorders. The spiroketal compounds are also useful as immunosuppressive agents, and also in methods of controlling pests.Type: ApplicationFiled: August 11, 2011Publication date: February 9, 2012Applicant: ECOBIOTICS LTDInventors: Paul Warren Reddell, Victoria Anne Gordon
-
Publication number: 20120020877Abstract: An intrauterine device and more specifically an intracervical device (ICD) for the local release of drugs in the loco-regional treatment of tumours of the uterine cervix comprises an elongated stem (2) to be positioned in the cervical canal (15), this stem consisting of an inner hollow core (3) and a coating (4) containing a gradual-release drug, the stem being attached to: a first element (5) for blocking the stem (2) inside the uterine cavity (12), and located at the cranial or upper end; a second blocking element (7, 71) positioned inside the vagina (11), against the ectocervix (16), located at the caudal or lower end of the stem (2).Type: ApplicationFiled: January 29, 2009Publication date: January 26, 2012Applicant: Fondazione IRCSSInventor: Francesco Raspagliesi
-
Patent number: 8101758Abstract: A stereoselective process for preparing 7-[(E)-t-butyloxyiminomethyl]-camptothecin (also known as gimatecan) is herein disclosed. With the addition of further dissolution and precipitation steps carried out in appropriate different solvent mixtures, four new crystalline forms of gimatecan are also obtainable by using the same stereoselective process.Type: GrantFiled: August 17, 2010Date of Patent: January 24, 2012Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Paolo Carminati, Maria Ornella Tinti, Mauro Marzi, Fabrizio Giorgi, Walter Cabri, Marco Alpegiani, Domenico Vergani, Paolo Ghetti
-
Publication number: 20120015050Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.Type: ApplicationFiled: June 20, 2011Publication date: January 19, 2012Applicant: Myriad Genetics, IncorporatedInventors: Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
-
Publication number: 20120010161Abstract: The present invention relates to compounds of azapeptide or azapeptidomimetic type of formula (I): in which R1, R2, R3, X1, X2, X3, X4 and Y are as defined in claim 1, to pharmaceutical compositions containing them and to such compounds as adjuvant for an anticancer or anti-infectious medicament.Type: ApplicationFiled: January 25, 2010Publication date: January 12, 2012Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE CLAUDE BERNARD LYON IInventor: Joelle Paris
-
Publication number: 20120009243Abstract: The present invention provides liposomes that are useful for delivery of bioactive agents such as therapeutics. Among others, the liposomes of the invention are capable of delivering their payload at sites of increased secretory phospholipase A2 (sPLA2) activity, because phospholipase A2 (PLA2) will hydrolyse lipids of the liposome. Thus, the liposomes of the invention may e.g. be used in relation to cancer therapy. Another aspect of the invention is a liposomal formulation comprising the liposome of the invention. Still another aspect is a method of producing a liposomal formulation of the invention.Type: ApplicationFiled: May 25, 2009Publication date: January 12, 2012Applicant: LIPLASOME PHARMA APSInventors: Anders Falk Vikbjerg, Sune Allan Petersen, Fredrik Melander, Jonas Rosager Henriksen, Kent Jørgensen
-
Patent number: 8092840Abstract: A nutritional supplement for enhancing sleep and lucid dreaming in humans. It contains a combination of ingredients in proportions calculated to enhance lucid dreaming. The primary ingredients are Calea ternifolia, L-5-Hydroxytryptophan (L-5-HTP), and Vinpocetine. In addition, the nutritional supplement may include the secondary ingredient Melatonin and the tertiary ingredients Wild Lettuce Extract, Mugwort Extract, Dimethylaminoethanol Powder (DMAE), Passionflower Extract and Green Tea Extract. Further, various Vitamins may be added such as certain B vitamins, D and C, as well as Zinc, Magnesium and Calcium. The selection and amounts of the ingredients of the nutritional supplement promotes sleep and lucid dreaming in people who have taken the nutritional supplement prior to going to sleep.Type: GrantFiled: October 30, 2007Date of Patent: January 10, 2012Inventor: Jeff Luciano
-
Publication number: 20120003321Abstract: The present invention relates to crosslinked dextran magnetic composite microparticles and a preparation process and a using method thereof. The composite microparticles comprise magnetic nanoparticles and dextran with crosslinked structure, wherein the magnetic nanoparticles are dispersed in the dextran with crosslinked structure. The process for preparing the composite microparticles comprises: preparing a dextran solution; synthesizing dextran magnetic composite microparticles; and synthesizing the crosslinked dextran magnetic composite microparticles. The using method of composite microparticles comprises: preparing crosslinked dextran magnetic composite microparticles loaded with anti-cancer drug; and adding a sustained-releasing solution thereto.Type: ApplicationFiled: December 29, 2008Publication date: January 5, 2012Applicant: XI'AN GOLDMAG NANOBIOTECH CO. LTD.Inventors: Mingli Peng, Yanhong Liu, Yali Cui, Chao Chen, Ke Li
-
Publication number: 20120003297Abstract: This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.Type: ApplicationFiled: February 1, 2011Publication date: January 5, 2012Applicant: TALON THERAPEUTICS, INC.Inventors: Andreas SARRIS, Fernando CABANILLAS, Patricia M. LOGAN, Clive T.R. BURGE, James H. GOLDIE, Murray S. WEBB
-
Publication number: 20120003177Abstract: Curcumin, a polyphenol extracted from the rhizome turmeric, has been polymerized to produce a polymer material having a backbone of one or more repeating structural units, at least one of which comprises a curcumin monomer residue. These curcumin-containing polymers have a wide range of pharmacological activities, including, among others antitumor, antioxidant, antiinflammatory, antithrombotic and antibacterial activities. Certain species of these polymers have exhibited remarkable antitumor activity. Water-soluble curcumin derivatives and their use as prodrugs and prodrug carriers are also disclosed.Type: ApplicationFiled: September 17, 2009Publication date: January 5, 2012Inventors: Youqing Shen, Huadong Tang, Edward Van Kirk, William Murdoch, Maciej Radosz
-
Publication number: 20120003309Abstract: In the present invention there is provided a pharmaceutical composition in a solid dosage form suitable for oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5.Type: ApplicationFiled: December 3, 2009Publication date: January 5, 2012Applicant: ASTELLAS DEUTSCHLAND GMBHInventors: Jeffrey Colledge, Thomas Alfred Profitlich, Ulrich Patzak, Taoufik Ouatas, Margaretha Olthoff
-
Publication number: 20120004255Abstract: The present invention relates to conjugate comprising a carrier substituted with one or more occurrences of a moiety having the structure: wherein each occurrence of M is independently a modifier having a molecular weight ?10 kDa; denotes direct of indirect attachment of M to linker LM; and each occurrence of LM is independently an optionally substituted succinamide-containing linker, whereby the modifier M is directly or indirectly attached to the succinamide linker through an amide bond, and the carrier is linked directly or indirectly to each occurrence of the succinamide linker through an ester bond. In another aspect, the invention provides compositions comprising the conjugates, methods for their preparation, and methods of use thereof in the treatment of various disorder, including, but not limited to cancer.Type: ApplicationFiled: June 3, 2011Publication date: January 5, 2012Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Mikhail I. Papisov, Alexander Yurkovetskiy
-
Publication number: 20120003305Abstract: In the present invention there is provided an oral pharmaceutical composition, comprising bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient, which is a pharmaceutically acceptable non-ionic surfactant, selected from the group consisting of polyethoxylated castor oil or derivative thereof and a block copolymer of ethylene oxide and propylene oxide.Type: ApplicationFiled: December 3, 2009Publication date: January 5, 2012Applicant: ASTELLAS DEUTSCHLAND GMBHInventors: Jeffrey Colledge, Margaretha Olthoff
-
Publication number: 20110319354Abstract: The invention relates to combination anticancer therapy with certain Akt inhibitor and other anticancer agents such as anticancer antimetabolites, anticancer antibiotics, plant-derived anticancer agents, anticancer platinum-coordinated complex compounds, anticancer camptothecin derivatives and anticancer tyrosine kinase inhibitors.Type: ApplicationFiled: February 23, 2010Publication date: December 29, 2011Inventors: Mark E. Layton, Hiroshi Hirai, Hidehito Kotani
-
Publication number: 20110311648Abstract: Compositions and methods for the treatment of malignancy and chronic viral infection are disclosed.Type: ApplicationFiled: July 20, 2011Publication date: December 22, 2011Inventors: George C. Prendergast, Alexander J. Muller, James B. DuHadaway, William Malachowski
-
Patent number: 8080559Abstract: A 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diasterisomer is described which is a better inhibitor of topoisomerase I than either the diastereoisomeric mixture 5(RS)-(2?-hydroxyethoxy)-20(S)-camptothecin, or the 5(R)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer. Pharmaceutical compositions of the 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer are also described as are methods of using the compound for the inhibition of topoisomerase I and for the treatment of cancer.Type: GrantFiled: October 12, 2009Date of Patent: December 20, 2011Assignees: Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories, Inc.Inventors: Venkateswarlu Akella, Shanavas Alikunju, Ajaya Kumar Reka, Ramesh Mullangi, Raju Sirisilla, Subrahmanyam Duvvuri, Sriram Rajagopal
-
Publication number: 20110301188Abstract: This invention is based on the discovery that the administration of a sphingosine-1-phosphate receptor antagonist (S1P) and at least one chemotherapeutic agent selected from the the group of antimicrotubule agents provides an unexpectedly superior treatment for cancer. Antimicrobial agents such as the taxane compounds are known in the art, for example, paclitaxel (available as TAXOL® from Bristol-Myers Squibb, Princeton, N.J.), docetaxel (available as TAXOTERE® from Sanofi-aventis, Bridgewater, N.J.) and the like and other compounds that act as antimicrotubule agents, such as Vincristine (ONCOVIN®, VINCASAR PFS®, VCR), Vinblastin (VELBAN®, VELSAR®) and Vinorelbine, and similar compounds. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one sphingosine-1-phosphate 1 (S1P1R) receptor antagonists, and at least one antimicrotubule agent.Type: ApplicationFiled: October 16, 2009Publication date: December 8, 2011Applicant: EXELIXIS, INC.Inventors: Geetha Shankar, Frauke Bentzien, Peter Lamb, David Matthews
-
Publication number: 20110300187Abstract: The present invention is directed to antioxidant derivatives of camptothecin and antioxidant derivatives of camptothecin analogs and the preparation of nanometer-sized camptothecin prodrugs. Methods of synthesizing the antioxidant derivatives of camptothecin and antioxidant derivatives of camptothecin analogs, spontaneous emulsification or nanoprecipitation thereof to produce antioxidant camptothecin nanosphere prodrugs and their use in treating cancerous diseases are also provided. A further aspect of this invention is the use of these antioxidant camptothecin nanosphere prodrugs for the preparation of delivery devices of other pharmaceuticals and/or drugs. Additionally, methods of treating cancer with the camptothecin and antioxidant derivatives of camptothecin analogs, and nanometer-sized camptothecin prodrugs are also provided.Type: ApplicationFiled: May 24, 2011Publication date: December 8, 2011Applicant: CEDAR- SINAI MEDICAL CENTERInventors: John S. Yu, Bong Seop Lee
-
Publication number: 20110293746Abstract: There is provided methods and uses for promoting cell death, when combined with chemotherapeutic agents, in an abnormally proliferating cell, and for treating a proliferative disorder in a subject, which methods and uses involve contacting a cell with, or administering to a subject, an agent that modulates glycogen synthase kinase-3? activity to a cell that is being treated with a chemotherapeutic agent.Type: ApplicationFiled: July 8, 2005Publication date: December 1, 2011Inventor: Qiang Yu
-
Publication number: 20110294754Abstract: Novel compounds and pharmaceutical compositions are provided. In one aspect of the invention the compounds may be utilized in medical practice, for example, in treatment of cancer and immune disorders.Type: ApplicationFiled: June 1, 2010Publication date: December 1, 2011Inventors: Ilan ZIV, Hagit Grimberg
-
Publication number: 20110293672Abstract: There is provided a composition comprising microspheres which comprise a water-insoluble, water-swellable polymer and associated with the polymer, in releasable form, a chemotherapeutic agent, for use in the treatment of a pancreatic tumour or cyst, wherein the microspheres, when equilibrated in water at 37° C., comprise at least 40 wt % water based on weight of polymer plus water, wherein the polymer is anionically charged at pH7 and the chemotherapeutic agent is cationically charged and electrostatically associated with the polymer. Also provided are methods of treating pancreatic tumours or cysts using this composition.Type: ApplicationFiled: November 25, 2009Publication date: December 1, 2011Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard Lewis, Peter William Stratford, Richard Edward John Forster
-
Publication number: 20110293744Abstract: Inhibitors of poly(ADP-ribose)polymerase having a structure of Formula (I), ways to make them and methods of treating patients using them are disclosed.Type: ApplicationFiled: January 19, 2010Publication date: December 1, 2011Applicant: ABBOTT LABORATORIESInventors: Magdalena K. Przytulinska, Thomas D. Penning, Yunsong Tong
-
Publication number: 20110293558Abstract: The invention in some aspects relates to methods, devices and compositions for evaluating material properties, such as mechanical and rheological properties of substances, particularly biological substances, such as cells, tissues, and biological fluids. In some aspects, the invention relates to methods, devices and compositions for evaluating material properties of deformable objects, such as cells. In further aspects, the invention relates to methods, devices and compositions for diagnosing and/or characterizing disease based on material properties of biological cells.Type: ApplicationFiled: March 21, 2011Publication date: December 1, 2011Applicant: Massachusetts Institute of TechnologyInventors: Subra Suresh, Jianzhu Chen, Irene Yin-Ting Chang
-
Patent number: 8067432Abstract: A method for preparing a stable dispersion of a camptothecin, camptothecin prodrug, or analog thereof for administration to a patient in need thereof includes preparing a solution of the camptothecin, wherein the solution has a pH which places substantially an entirety of that camptothecin in a carboxylate form. The camptothecin may be a neutral camptothecin. The solution is next loaded into a liposome including at least one lipid, which may be a phospholipid. An intraliposomal pH is maintained which preserves substantially an entirety of the camptothecin in the carboxylate form. The liposomal dispersion is administered to an individual in need thereof, whereby the liposomes accumulate at and permeate into tumor tissue and an active, lactone form camptothecin is released in situ at the tumor site. Compositions formulated in accordance with the described method for treatment of a cancer in an animal in need thereof are provided also.Type: GrantFiled: March 31, 2008Date of Patent: November 29, 2011Assignee: University of Kentucky Research FoundationInventors: Bradley D. Anderson, Vijay Joguparthi, Tian-Xiang Xiang
-
Patent number: 8066971Abstract: This invention provides novel compositions and methods for the specific and/or preferential delivery of an effector (e.g. a drug or label) to an epithelial cell (e.g. a pulmonary epithelium). The compositions comprise an adipocyte differentiation-related protein (ADRP) attached to an effector thereby forming a chimeric moiety. The chimeric moiety is preferentially delivered to epithelial cells.Type: GrantFiled: April 3, 2006Date of Patent: November 29, 2011Assignee: Los Angeles Biomedical Reseach Institute at Harbor UCLA Medical CenterInventors: John S. Torday, Virender K. Rehan
-
Publication number: 20110286915Abstract: The present invention provides a nanocarrier having an interior and an exterior, the nanocarrier comprising at least one conjugate, wherein each conjugate includes a polyethylene glycol (PEG) polymer. Each conjugate also includes at least two amphiphilic compounds having both a hydrophilic face and a hydrophobic face. In addition, each conjugate includes an oligomer, wherein at least 2 of the amphiphilic compounds are covalently attached to the oligomer which is covalently attached to the PEG. The nanocarrier is such that each conjugate self-assembles in an aqueous solvent to form the nanocarrier such that a hydrophobic pocket is formed in the interior of the nanocarrier by the orientation of the hydrophobic face of each amphiphilic compound towards each other, and wherein the PEG of each conjugate self-assembles on the exterior of the nanocarrier.Type: ApplicationFiled: September 22, 2009Publication date: November 24, 2011Applicant: The Regents of the University of CaliforniaInventors: Kit S. Lam, Juntao Luo
-
Publication number: 20110286993Abstract: The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP.Type: ApplicationFiled: June 26, 2009Publication date: November 24, 2011Inventors: Thomas Kirkegaard Jensen, Marja Helena Jaattela
-
Publication number: 20110286927Abstract: In one aspect, the invention relates to a method for identifying a drug candidate with activity as a neuroprotective agent. The method includes determining whether a compound reduces ATF4 activity; and identifying the compound that reduces ATF4 activity as a drug candidate.Type: ApplicationFiled: August 4, 2008Publication date: November 24, 2011Applicant: CORNELL UNIVERSITYInventor: Rajiv R. Ratan
-
Publication number: 20110280860Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.Type: ApplicationFiled: March 3, 2011Publication date: November 17, 2011Inventors: Thomas Chen, Daniel Levin, Satish Puppali
-
Publication number: 20110274625Abstract: Convection-enhanced delivery (CED) is used as a method to deliver a direct infusion of therapeutic agents to the central nervous centre thus circumventing the blood-blood barrier. A non-PEGylated liposomal composition comprising at least one saturated neutral phospholipid and at least one saturated anionic phospholipid and a therapeutic or diagnostic agent encapsulated therein is used to overcome toxicity associated with high peak drug concentration delivered locally CED as well as to increase tissue distribution volume for an improved sustained drug release.Type: ApplicationFiled: November 23, 2009Publication date: November 10, 2011Applicant: MedGenesis Therapeutix ,Inc.Inventors: Thomas Redelmeier, Matthias Luz
-
Publication number: 20110270011Abstract: The use of opioids or opioid mimetics is suggested for the manufacture of a medicament for the treatment of resistant cancer patients.Type: ApplicationFiled: January 29, 2009Publication date: November 3, 2011Applicant: Universität UlmInventors: Erich Miltner, Claudia Friesen, Andreas Alt
-
Publication number: 20110269789Abstract: Provided herein are compounds and methods for achieving a sustained therapeutic effect of small molecule anti-cancer agents when administered in vivo.Type: ApplicationFiled: September 23, 2009Publication date: November 3, 2011Applicant: Nektar TherapeuticsInventors: Michael A. Eldon, Shibani S. Harite, Tamra L. Barker
-
Publication number: 20110268803Abstract: The American Cancer Society estimated that in 2009, 1,479,350 new cancer cases would be diagnosed in the United States of which 219,440 would be lung and bronchus related. The standard treatments for NSCLC include surgery, chemotherapy, radiation, laser and photodynamic therapy, all with various success rates depending on the stage of the cancer. National Cancer Institute assesses, however, that results of standard treatment are generally poor with only a 15 percent 5-year survival rate for combined cancer stages. Challenges facing the current chemotherapy drugs include excessive toxicity to healthy tissues and limited ability to prevent metastases. A dual drug delivery system described herein selectively targets the lung to deliver anti-cancer drugs and inhibit the formation of metastases.Type: ApplicationFiled: April 5, 2011Publication date: November 3, 2011Applicants: Rutgers, The State University of New Jersey, THE TRUSTEES OF PRINCETON UNIVERSITYInventors: Robert K. Prud'homme, Patrick J. Sinko, Howard A. Stone, Nathalie M. Pinkerton, Lei Shi, Jiandi Wan, Sherif Ibrahim, Dayuan Gao
-
Patent number: 8048891Abstract: The present invention relates to methods of treatment of non-Hodgkin's lymphomas. The present invention includes administering polymeric prodrugs of 7-ethyl-10-hydroxycamptothecin to patients in need thereof.Type: GrantFiled: January 18, 2010Date of Patent: November 1, 2011Assignee: Enzon Pharmaceuticals, Inc.Inventor: Puja Sapra
-
Publication number: 20110262561Abstract: Disclosed herein are novel protoilludane norsesquiterpenoid ester compounds isolated from mycelium of Armillaria mellea that are useful for treating tumors or proliferative diseases such as breast cancers, lung cancers, colon cancers or leukemia.Type: ApplicationFiled: April 25, 2011Publication date: October 27, 2011Applicant: NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINEInventors: Chien-Chih Chen, Jing-Jy Cheng, Chien-Chang Shen
-
Publication number: 20110262524Abstract: The present invention relates to the use of copper ions to achieve enhanced retention of a therapeutic agent within a liposome. The invention may be employed to more effectively deliver a liposomally encapsulated therapeutic agent to a target site in vitro and in vivo for anti-cancer or other therapy. The liposome may comprise an interior buffer solution containing the therapeutic agent, the solution having a pH less than 6.5 and most preferably approximating pH 3.5. At least some of the copper ions are retained within the interior solution. In a particular embodiment the therapeutic agent may be a chemotherapeutic drug, such as irinotecan. The invention may also comprise an ionophore to facilitate loading of drug into the liposome. In one particular embodiment the combination of the ionophore A23187 and encapsulated divalent copper (Cu2+) resulted in an irinotecan formulation that exhibited surprisingly improved drug retention attributes.Type: ApplicationFiled: October 6, 2005Publication date: October 27, 2011Applicant: BC CANCER AGENCYInventors: Marcel Bally, Euan Ramsay
-
Publication number: 20110256212Abstract: 8-quinolinol (8Q) and derivatives thereof for use in the treatment of proliferative diseases such as cancer, in particular slow metabolizing quiescent cancer stem cells.Type: ApplicationFiled: February 22, 2011Publication date: October 20, 2011Applicant: The Johns Hopkins UniversityInventors: Ying Zhang, Jiangbing Zhou, Hao Zhang
-
Publication number: 20110243892Abstract: The present invention relates to Y-shape branched PEG derivatives of formulae (I) to (IV). The present invention also relates to conjugates of these Y-shape derivatives and drug molecules, pharmaceutical compositions comprising those conjugates.Type: ApplicationFiled: June 17, 2011Publication date: October 6, 2011Inventors: Shishan Ji, Dequan Zhu
-
Publication number: 20110245201Abstract: Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101.Type: ApplicationFiled: March 14, 2011Publication date: October 6, 2011Inventors: John Ryan, Thomas Schluep, Yun Yen, James C. Oliver, Mark Davis
-
Patent number: 8030492Abstract: Compositions containing neurogenic agents for inhibition of neuron death and inducing proliferation of neural cells are disclosed.Type: GrantFiled: November 4, 2010Date of Patent: October 4, 2011Assignee: Neuralstem, Inc.Inventors: Judith Kelleher-Andersson, Karl K. Johe
-
Publication number: 20110236472Abstract: A drug delivery system (DDS) for administration of a water soluble, cationic, and amphiphilic pharmaceutically active substance (API) which DDS comprises amorphous particles of <100 nm of a poorly water soluble complex of the API with a Na-salt of N-all-trans-retinoyl cysteic acid methyl ester and/or a Na-salt of N-13-cis-retinoyl cysteic acid methyl ester, which particles are entrapped in nanoparticles formed a Na-salt of N-all-trans-retinoyl cysteic acid methyl ester and/or a Na-salt of N-13-cis-retinoyl cysteic acid methyl ester, the w/w-ratio of Na-salt of N-alltrans-retinoyl cysteic acid methyl ester and/or a Na-salt of N-13-cis-retinoyl cysteic acid methyl ester to the complex is about 0.5:1 to about 20:1. A pharmaceutical composition comprising such a DDS. Methods for preparation of such a DDS and such a pharmaceutical composition. Use of such a DDS and pharmaceutical composition for treatment of cancer.Type: ApplicationFiled: December 18, 2008Publication date: September 29, 2011Applicant: ARDENIA INVESTMENTS, INC.Inventors: Julian Aleksov, Igor Lokot
-
Patent number: 8026250Abstract: The present invention provides compositions for delivering highly water-soluble drugs (such as vinca alkaloids) and methods of using such compositions.Type: GrantFiled: December 10, 2010Date of Patent: September 27, 2011Assignee: Adventrx Pharmaceuticals, Inc.Inventor: Andrew Xian Chen
-
Patent number: 8026249Abstract: The present application describes deuterium-enriched topotecan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: GrantFiled: September 8, 2008Date of Patent: September 27, 2011Assignee: Deutena Pharmaceuticals, Inc.Inventor: Anthony W. Czarnik